CME Presentations
COVID Treatment - Rapid Education
Presentations
Detecting COVID-19 Earlier in High-Risk Patients: Guidance for Primary Care
Speakers: Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM, Professor of Pediatrics and Internal MedicineCharles Vega, Health Sciences Clinical Professor, Department of Family Medicine Duration: 30 minutes
Presented on: January 26, 2023
Choosing a COVID-19 Therapy for High-Risk Patients: Guidance for Primary Care
Speakers: Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM, Professor of Pediatrics and Internal MedicineCharles Vega, Health Sciences Clinical Professor, Department of Family Medicine Duration: 30 minutes
Presented on: January 26, 2023
Speakers
Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM
Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM
Professor of Pediatrics and Internal Medicine
Tamera Coyne-Beasley, MD, is the Derrol Dawkins Endowed Chair in Adolescent Medicine, Division Director for Adolescent Medicine, Vice Chair of Pediatrics for Community Engagement, and Professor of Pediatrics and Internal Medicine at the University of Alabama at Birmingham and Children’s of Alabama. Her areas of expertise include adolescent medicine, preventive medicine, health services research, epidemiology, and public health. Her research and policy and program development focus on adolescent health and well-being, sexual and reproductive health, risk behaviors and resiliency, global health, immunizations, health disparities and equity. Dr. Coyne-Beasley has tackled sensitive issues that arose on race and its impact on the health of children and adolescents as President of the SAHM.
Charles Vega
Charles Vega
Health Sciences Clinical Professor, Department of Family Medicine
Charles Vega, MD, is the Health Sciences Clinical Professor in the Department of Family Medicine at UC Irvine (UCI). Also, he is the Executive Director of UCI’s Program in Medical Education for the Latino Community and won a Macy Faculty Scholarship to improve patient-centered health education at UCI. Currently, Dr. Vega serves as Assistant Dean for Culture and Community Education in the UCI School of Medicine. His academic interests are focused on access to quality, compassionate medical care for underserved populations, and the development of training programs to promote this vision of healthcare. Dr. Vega has seen patients and taught medical students and residents at UCI’s Family Health Center, a federally qualified health center and the largest safety-net clinic for Orange County.
CME Information
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.Choosing a COVID-19 Therapy for High-Risk Patients: Guidance for Primary Care
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Pfizer Inc.LIVE RELEASE DATE
Thursday January 26, 2023 from 12:45pm-1:15pm ET.TARGET AUDIENCE
The educational design of this activity addresses the needs of primary care physicians, including NP and PA, who treat patients with mild-to-mod COVIDSTATEMENT OF NEED/PROGRAM OVERVIEW
As the COVID-19 pandemic evolves and guidelines for treatment are updated, morbidity and mortality remain much higher for patients with risk factors associated with progression from mild or moderate disease to severe COVID-19. Primary care clinicians are in a unique position to identify and initiate guideline-directed therapy in high-risk patients, while also ensuring they receive appropriate counseling and preparation for testing and treatment.
Join a panel of primary care clinicians with expertise in diagnosing and managing COVID-19 for two easy-to-digest educational sessions designed to help clinicians risk-stratify patients, provide appropriate test selection for diagnosis, and ensure early guideline-directed treatment of high-risk patients. Session 1, “Detecting COVID-19 Earlier in High-Risk Patients: Guidance for Primary Care,” will help clinicians stay up to date with the latest guidelines for identifying patients at high risk for severe COVID and select suitable diagnostic methods.
Session 2, “Choosing a COVID-19 Therapy for High-Risk Patients: Guidance for Primary Care,” will explore available antiviral and immunomodulatory therapies for arresting disease progression in both pediatric and adult patients. Panelists will also share strategies for counseling patients and parents about treatment benefits/risks and follow-up strategies.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Formulate an appropriate treatment strategy to prevent severe COVID-19 illness in high-risk patients
- Apply guidelines for diagnosis and treatment to clinical case scenarios
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Name of Faculty or Presenter Conflicts of Interest Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM
Derrol Dawkins, MD Endowed Chair in Adolescent Medicine
Professor of Pediatrics and Internal Medicine
Division Director, UAB Adolescent Medicine
Vice Chair, Pediatrics for Community Engagement
Advisor, Consultant, Speaker: Pfizer, Moderna, Sanofi Pasteur, Seqirus Charles Vega MD,
Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
Director, Program in Medical Education for the Latino Community (PRIME-LC)
UC Irvine School of Medicine
Advisor, Consultant: Boehringer Ingelheim GlaxoSmithKline, Johnson and Johnson
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.Technical Support:
For any technical issues or issues with your CME Certificate, please contact IDCareLive or ClinicalSeriesLive at 877-394-1306 or at Support@IDCareLive.com or Support@ClinicalSeriesLive.com.
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.Detecting COVID-19 Earlier in High-Risk Patients: Guidance for Primary Care
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Pfizer Inc.LIVE RELEASE DATE
Thursday January 26, 2023 from 12:15pm-12:45pm ET.TARGET AUDIENCE
The educational design of this activity addresses the needs of primary care physicians, including NP and PA, who treat patients with mild-to-mod COVIDSTATEMENT OF NEED/PROGRAM OVERVIEW
As the COVID-19 pandemic evolves and guidelines for treatment are updated, morbidity and mortality remain much higher for patients with risk factors associated with progression from mild or moderate disease to severe COVID-19. Primary care clinicians are in a unique position to identify and initiate guideline-directed therapy in high-risk patients, while also ensuring they receive appropriate counseling and preparation for testing and treatment.
Join a panel of primary care clinicians with expertise in diagnosing and managing COVID-19 for two easy-to-digest educational sessions designed to help clinicians risk-stratify patients, provide appropriate test selection for diagnosis, and ensure early guideline-directed treatment of high-risk patients. Session 1, “Detecting COVID-19 Earlier in High-Risk Patients: Guidance for Primary Care,” will help clinicians stay up to date with the latest guidelines for identifying patients at high risk for severe COVID and select suitable diagnostic methods.
Session 2, “Choosing a COVID-19 Therapy for High-Risk Patients: Guidance for Primary Care,” will explore available antiviral and immunomodulatory therapies for arresting disease progression in both pediatric and adult patients. Panelists will also share strategies for counseling patients and parents about treatment benefits/risks and follow-up strategies.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Articulate the importance of early diagnosis of high-risk patients with mild-to-moderate COVID-19 course
- Describe clinical considerations when selecting a COVID-19 diagnostic method for high-risk patients
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CONTINUING EDUCATION
PACE designates this live activity for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Name of Faculty or Presenter Conflicts of Interest Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM
Derrol Dawkins, MD Endowed Chair in Adolescent Medicine
Professor of Pediatrics and Internal Medicine
Division Director, UAB Adolescent Medicine
Vice Chair, Pediatrics for Community Engagement
Advisor, Consultant, Speaker: Pfizer, Moderna, Sanofi Pasteur, Seqirus Charles Vega MD,
Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
Director, Program in Medical Education for the Latino Community (PRIME-LC)
UC Irvine School of Medicine
Advisor, Consultant: Boehringer Ingelheim GlaxoSmithKline, Johnson and Johnson
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.Technical Support:
For any technical issues or issues with your CME Certificate, please contact IDCareLive or ClinicalSeriesLive at 877-394-1306 or at Support@IDCareLive.com or Support@ClinicalSeriesLive.com.
